Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Atossa Therapeutics, a clinical stage biopharmaceutical company focused on developing innovative medicines for breast cancer and other areas of significant unmet medical need in oncology, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. Michael Parks, Vice President of Investor and Public Relations at Atossa, will engage in a virtual fireside chat on Wednesday, October 16, 2024, at 12:00 p.m. EDT.
The company, traded on Nasdaq under the ticker ATOS, invites interested parties to register and access the live webcast of the conference through a provided link. This event presents an opportunity for investors and stakeholders to gain insights into Atossa's current developments and future prospects in the oncology field.
Details
News Market Reaction – ATOS
The recorded move for ATOS in the trading session of this news was +0.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that Michael Parks, Vice President, Investor and Public Relations, will participate in a virtual fireside chat on Wednesday, October 16, 2024 at 12:00 p.m. EDT at the 2024 Maxim Healthcare Virtual Summit. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Interested parties can register and access the live webcast for the conference here.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.
Contact:
Michael Parks
Vice President, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.